HBMH.F Stock Overview
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HBM Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.48 |
| 52 Week High | HK$0.48 |
| 52 Week Low | HK$0.48 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| HBMH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.9% | 3.3% |
| 1Y | n/a | 3.4% | 25.8% |
Return vs Industry: Insufficient data to determine how HBMH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HBMH.F performed against the US Market.
Price Volatility
| HBMH.F volatility | |
|---|---|
| HBMH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HBMH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HBMH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 396 | Jingsong Wang | www.harbourbiomed.com |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors.
HBM Holdings Limited Fundamentals Summary
| HBMH.F fundamental statistics | |
|---|---|
| Market cap | US$362.31m |
| Earnings (TTM) | -US$137.78m |
| Revenue (TTM) | US$4.31m |
84.1x
P/S Ratio-2.6x
P/E RatioIs HBMH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBMH.F income statement (TTM) | |
|---|---|
| Revenue | US$4.31m |
| Cost of Revenue | US$137.00k |
| Gross Profit | US$4.17m |
| Other Expenses | US$141.95m |
| Earnings | -US$137.78m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 96.82% |
| Net Profit Margin | -3,198.17% |
| Debt/Equity Ratio | 5.4% |
How did HBMH.F perform over the long term?
See historical performance and comparison